| Identification | Back Directory | [Name]
Ro 5-3335 | [CAS]
30195-30-3 | [Synonyms]
Ro 5-3335
NSC-66020
CBFβ-Runx1 inhibitor II
CBFβ-Runx1 inhibitor II
7-Chloro-5-(1H-pyrrol-2-yl)-1H-benzo[e][1,4]diazepin-2(3H)-one
7-Chloro-5-(1H-pyrrol-2-yl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one
7-Chloro-1,3-dihydro-5-(1H-pyrrol-2-yl)-2H-1,4-benzodiazepin-2-one
7-Chloro-2-oxo-5-(1H-pyrrol-2-yl)-2,3-dihydro-1H-1,4-benzodiazepine
2H-1,4-Benzodiazepin-2-one, 7-chloro-1,3-dihydro-5-(1H-pyrrol-2-yl)-
Ro5-3335,Ro53335,CBFβ,inhibit,binding,Ro-5-3335,core,RUNX1,RUNX1-CBFB,factor,CBF,interaction,leukemia,Inhibitor,Ro5 3335 | [Molecular Formula]
C13H10ClN3O | [MDL Number]
MFCD00870704 | [MOL File]
30195-30-3.mol | [Molecular Weight]
259.69 |
| Hazard Information | Back Directory | [Uses]
Ro 5-3335 is a benzodiazepine is a core binding factor (CBF) leukemia inhibitor. | [Definition]
ChEBI: A 1,4-benzodiazepinone that is nordazepam in which the phenyl substituent has been replaced by a 1H-pyrrol-2-yl group. It inhibits gene expression in HIV-1 at the transcriptional level through interference with Tat-mediated transactivati
n. | [in vivo]
Ro5-3335 is identified as an inhibitor of RUNX1–CBFβ function in zebrafish models[1].
Ro5-3335 rescues preleukemic phenotype in a RUNX1-ETO transgenic zebrafish[1].
Ro5-3335 (300 mg/kg/d; p.o; for 30 days) reduces leukemia burden in a mouse CBFB-MYH11 leukemia model[1].
| Animal Model: | C57BL/6 mice (leukemic model)[1] | | Dosage: | 300 mg/kg | | Administration: | Oral administration; daily; for 30 days | | Result: | Reduced the number of c-kit+ cells in the transplanted mice and leukemic cell infiltration in the livers, bone marrow and spleen. |
| [storage]
Store at +4°C |
|
| Company Name: |
Energy Chemical
|
| Tel: |
021-58432009 400-005-6266 |
| Website: |
http://www.energy-chemical.com |
|